<DOC>
	<DOCNO>NCT00388427</DOCNO>
	<brief_summary>This open-label , safety study cetuximab differ dose level dasatinib adult patient advance solid malignancy . Cetuximab administer intravenous infusion weekly . Dasatinib take orally , day , continuous schedule differ dose level . The primary objective study determine toxicity maximum tolerated dos dasatinib combine cetuximab treatment advance solid tumor .</brief_summary>
	<brief_title>Safety Study Of Cetuximab Plus Dasatinib ( BMS-354825 ) Treating Advanced Solid Malignancies</brief_title>
	<detailed_description>This open-label , phase I study cetuximab differ dose level dasatinib adult patient advance solid malignancy . Cetuximab administer intravenous infusion standard dose schedule ( weekly , first dose 400 mg/m2 subsequent weekly dos 250 mg/m2 ) . Dasatinib administer orally continuous schedule follow dose level : 100 mg QD ( day ) , 150 mg QD , 200 mg QD . Three six patient enrol dose level , final recommend phase II cohort expand include 12 additional patient . The dos escalate successive cohort patient . On cycle 1 , dasatinib administration start one day prior cetuximab administration . One cycle define 21 day , cycle continue progression disease intolerable toxicity occur . Peripheral blood sample pharmacokinetic blood sample take day 0 , 1 , 15 , 16 Cycle 1 . In patient accessible tumor give consent , patient undergo baseline tumor biopsy repeat biopsy 14-21 day first cycle .</detailed_description>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Histologically cytologically confirm solid malignancy recurrent metastatic resistant therapy . Patients w/plan surgery recurrent disease post cetuximab/dasatinib eligible provide receive least 2 cycle therapy provide baseline posttreatment tumor tissue correlative . 2 . Any number prior regimen prior EGFR src inhibitor . 3 . Age great equal 18 year . 4 . ECOG performance status less equal 2 ( Karnofsky great equal 60 % ) . 5 . Life expectancy great 12 week . 6 . Patients must normal organ marrow function : leukocyte great equal 3,000/mcL absolute neutrophil count great equal 1,500/mcL platelet great equal 100,000/mcL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) less equal 2.5 X institutional upper limit normal creatinine 1.5 x normal institutional limit 7 . Ability understand willingness sign write informed Consent document . 8 . No concomitant medication CYP3A4 inducer potent inhibitor take proton pump inhibitor H2 antagonist first cycle therapy try avoid take proton pump inhibitor H2 antagonists rest treatment period . 9 . Sexually active woman childbearing potential must use effective method birth control course study , manner risk failure minimize . All WOCBP must negative pregnancy test prior first receive investigational product . 1 . Chemotherapy radiotherapy within 3 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier . 2 . Any concurrent investigational agent . 3 . Patients w/ untreated brain metastasis . However , patient stable brain disease ( corticosteroid ) least 4 week completion appropriate therapy eligible . 4 . History allergic reaction monoclonal antibody . 5 . Inability swallow oral medication unless patient use feed tube . 6 . Uncontrolled angina hypertension history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) . 7 . Prolonged QTc interval preentry electrocardiogram ( great 450 msec ) Fridericia Bazett 's correction . 8 . Diagnosed suspected congenital long QT syndrome . 9 . Patients currently take drug generally accept risk cause Torsades de Pointes include : quinidine , procainamide , disopyramide , amiodarone , sotalol , ibutilide , dofetilide , erythromycins , clarithromycin , chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . 10 . Any uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , psychiatric illness/social situation would limit compliance study requirement . 11 . History significant bleeding disorder unrelated cancer , include : diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) , diagnose acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) . 12 . HIVpositive patient receive combination antiretroviral therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>advanced cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>solid malignancy</keyword>
	<keyword>phase I</keyword>
</DOC>